REVB — Revelation Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- $3.12m
- -$11.43m
Annual balance sheet for Revelation Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 4.49 | 1.27 | 5.25 | 12 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 4.62 | 1.91 | 5.41 | 12.1 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0 | 0.13 | 0.09 | 0.065 |
| Total Assets | 4.62 | 2.04 | 5.5 | 12.2 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 1.21 | 2.14 | 4.45 | 5.56 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 1.21 | 2.14 | 4.45 | 5.56 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 3.41 | -0.099 | 1.05 | 6.65 |
| Total Liabilities & Shareholders' Equity | 4.62 | 2.04 | 5.5 | 12.2 |
| Total Common Shares Outstanding |